New study aims to crack the code of rare brain disease
NCT ID NCT05588167
First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 7 times
Summary
This study is creating the first large database for Niemann-Pick type C (NPC), a rare disease that damages the brain, liver, and spleen. Researchers will collect blood samples and medical records from 100 people with NPC to link their genes with their symptoms. The goal is to understand why the disease affects people so differently and to find clues for future treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this database could help researchers understand why NPC affects people differently and point toward new treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly help participants and may not lead to any new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NIEMANN-PICK DISEASE, TYPE C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill shows promise for rare brain disorders in early trial
- Hope for rare brain disease: new drug trial targets movement and daily life
- Promising drug tested for rare liver disease in newborns
- Search for NPC clues could speed future treatments
- Scientists dive into rare cholesterol disorders to uncover clues
- New york program offers extra screening for 100,000 newborns